Alexandria Capital LLC purchased a new stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 925,527 shares of the biopharmaceutical company’s stock, valued at approximately $15,179,000. Sangamo Therapeutics comprises 2.2% of Alexandria Capital LLC’s holdings, making the stock its 6th largest holding. Alexandria Capital LLC owned 1.10% of Sangamo Therapeutics at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of SGMO. State Street Corp boosted its holdings in shares of Sangamo Therapeutics by 51.6% during the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after buying an additional 636,296 shares during the period. California State Teachers Retirement System boosted its holdings in Sangamo Therapeutics by 5.0% in the 3rd quarter. California State Teachers Retirement System now owns 132,741 shares of the biopharmaceutical company’s stock valued at $1,991,000 after purchasing an additional 6,360 shares during the period. Russell Investments Group Ltd. boosted its holdings in Sangamo Therapeutics by 206.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 70,674 shares of the biopharmaceutical company’s stock valued at $1,060,000 after purchasing an additional 47,579 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in Sangamo Therapeutics by 143.9% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 19,942 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 11,766 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Sangamo Therapeutics by 53.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 100,176 shares of the biopharmaceutical company’s stock valued at $881,000 after purchasing an additional 34,913 shares during the period. Hedge funds and other institutional investors own 65.74% of the company’s stock.
SGMO has been the subject of a number of recent analyst reports. Barclays reaffirmed a “buy” rating and set a $30.00 price target on shares of Sangamo Therapeutics in a report on Sunday, February 25th. Jefferies Group reiterated a “buy” rating on shares of Sangamo Therapeutics in a research report on Friday, February 23rd. Piper Jaffray Companies set a $25.00 price target on shares of Sangamo Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. BidaskClub upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Finally, Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Wednesday, November 15th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $20.83.
In other news, VP Edward R. Conner sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $17.11, for a total value of $85,550.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Saira Ramasastry sold 9,450 shares of Sangamo Therapeutics stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $24.88, for a total transaction of $235,116.00. Following the sale, the director now owns 9,450 shares of the company’s stock, valued at $235,116. The disclosure for this sale can be found here. Insiders sold 90,403 shares of company stock valued at $1,907,369 in the last quarter. Corporate insiders own 5.50% of the company’s stock.
Shares of Sangamo Therapeutics Inc (SGMO) traded down $0.40 during mid-day trading on Wednesday, hitting $25.60. 1,471,758 shares of the stock traded hands, compared to its average volume of 2,490,000. The stock has a market capitalization of $2,210.00, a P/E ratio of -36.06 and a beta of 2.60. The company has a debt-to-equity ratio of 0.13, a quick ratio of 5.54 and a current ratio of 5.54. Sangamo Therapeutics Inc has a 52 week low of $3.85 and a 52 week high of $27.50.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The business had revenue of $13.08 million during the quarter, compared to the consensus estimate of $11.10 million. During the same quarter last year, the company posted ($0.14) earnings per share. The firm’s quarterly revenue was up 46.6% compared to the same quarter last year. equities research analysts predict that Sangamo Therapeutics Inc will post 0.04 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This article was reported by Equities Focus and is the property of of Equities Focus. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.equitiesfocus.com/2018/03/14/alexandria-capital-llc-purchases-new-position-in-sangamo-therapeutics-inc-sgmo.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.